Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 6/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TACR3 | P29371 | 6/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577055 | 0.84 | TACR3 (0.65) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL3576487 | 0.83 | TACR3 (0.70) | TACR3 | |
| SCHEMBL3576483 | 0.83 | TACR3 (0.70) | TACR3 | |
| SCHEMBL3582790 | 0.82 | DHODH (0.58) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL3590211 | 0.81 | TACR3 (0.79) | TSHRCYP2D6CYP2C19TACR3 | |
| SCHEMBL3580153 | 0.81 | DHODH (0.57) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL3585355 | 0.79 | DHODH (0.54) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL3629848 | 0.78 | DHODH (0.53) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL3591336 | 0.78 | DHODH (0.53) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL3594333 | 0.76 | DHODH (0.51) | DHODHPDE10ALMNATSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| EP-1968944-A1 | ALKYLSULPHONAMIDE QUINOLINES | AstraZeneca AB (SE) | 2008-09-17 | — | — | EP | claimed |
| US-20080021062-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | claimed |
| WO-2007069977-A1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| US-8071621-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071621-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071621-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | SIMPSON THOMAS | 2010-02-04 | — | — | US | disclosed |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | SIMPSON THOMAS | 2010-02-04 | — | — | US | disclosed |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | SIMPSON THOMAS | 2010-02-04 | — | — | US | disclosed |
| US-7608628-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-7608628-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-7608628-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1968944-A1 | ALKYLSULPHONAMIDE QUINOLINES | AstraZeneca AB (SE) | 2008-09-17 | — | — | EP | disclosed |
| US-20080021062-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | disclosed |
| WO-2007069977-A1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007069977-A1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021062-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DHODH 2436/4885PDE10A 614/4885LMNA 1750/4885 |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, QDPR | DHODH 2352/4885PDE10A 609/4885LMNA 1677/4885 |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, QDPR | DHODH 2352/4885PDE10A 609/4885LMNA 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.